Rainbow Children's Medicare (RAINBOW) Q2 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 26/27 earnings summary
2 Nov, 2026Executive summary
Q2 FY27 revenue from operations was ₹5,480.23 Mn, up 23.2% YoY; PAT was ₹838.93 Mn, up 10.9%, and post-Ind AS 116 EBITDA rose 14.2% to ₹1,699.8 Mn.
H1 FY27 revenue from operations increased 27.6% to ₹10,180.08 Mn; PAT rose 13.1% to ₹1,464.33 Mn and post-Ind AS 116 EBITDA grew 20.6% to ₹3,046.3 Mn.
The network had 26 hospitals across 11 cities and 2,685 current-capacity beds; Nellore and Guntur began operations in September 2026.
Financial highlights
Q2 total income was ₹5,561.49 Mn, up 22.8% YoY; total expenses rose 26.8% to ₹4,446.45 Mn and PBT increased 8.9% to ₹1,115.04 Mn.
Q2 pre-Ind AS 116 EBITDA excluding other income was ₹1,424.3 Mn, up 13.5% YoY; H1 was ₹2,506.5 Mn, up 21.2%.
Q2 EBITDA margin was 31.0% versus 33.5% YoY, and PAT margin was 15.3% versus 17.0%; H1 EBITDA margin was 29.9% versus 31.7%.
H1 total expenses increased 29.3% to ₹8,433.9 Mn, including doctor fees up 33.3% to ₹2,641.2 Mn and employee benefits expense up 28.6% to ₹1,420.3 Mn.
Outlook and guidance
Management framed revenue growth expectations in the high teens; the pre-Ind AS EBITDA margin target remains 25%-26%, with temporary 0.5%-1% compression possible as new capacity ramps up.
Capacity plans target 3,875 beds by FY30 and 5,000+ by FY32, with 1,190 identified additions through FY30 and ~1,125 further additions under discussion for FY28-FY32.
Planned projects include Gurugram, Indore, Pune, Seegehalli, Nellore Phase 2, Coimbatore, Amaravati and Mumbai; Mumbai is likely to commence by Q1 FY28 and Coimbatore in H2 FY27-28.
Most new hospitals are expected to reach EBITDA break-even in under two years; Delhi NCR hospitals are targeted to break even within two years.
Mature hospitals target ~60% occupancy, with margins expected to remain similar or improve slightly; ARPOB growth guidance is 7%-8%.
Latest events from Rainbow Children's Medicare
- Revenue rose 50% as volumes recovered; IPO and 1,000 planned beds set the growth agenda.RAINBOW
Q4 21/22 - FY23 growth accelerated as patient volumes rose and a 1,000-bed expansion plan took shape.RAINBOW
Q4 22/23 - Record revenue and EBITDA, with 280 beds added amid a broad expansion push.RAINBOW
Q4 23/24 - Q1 FY27 revenue up 33% and PAT up 16%, with major expansion and clinical excellence.RAINBOW
Q1 26/27 - Q3 FY26 revenue up 12%, profit rises, network expands, and new CEO appointed.RAINBOW
Q3 25/26 - Q2 FY26 revenue up 6.5% YoY, major acquisitions and new CEO support strong growth outlook.RAINBOW
Q2 25/26 - Q1 FY25 revenue up 15% YoY, EBITDA up 6.9%, with expansion, capex, and top accreditations.RAINBOW
Q1 24/25 - Q2 FY25 saw 25% revenue and profit growth, strong margins, and continued expansion.RAINBOW
Q2 24/25 - FY25 revenue up 17% YoY, margins strong, dividend proposed, and major expansion planned.RAINBOW
Q4 24/25